<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04177862</url>
  </required_header>
  <id_info>
    <org_study_id>ANES-2019-28303</org_study_id>
    <nct_id>NCT04177862</nct_id>
  </id_info>
  <brief_title>Sublingual Sufentanil vs Intravenous Fentanyl for Acute Pain in the Ambulatory Surgery Center</brief_title>
  <official_title>Sublingual Sufentanil vs Intravenous Fentanyl for Acute Pain in the Ambulatory Surgery Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a single dose of sublingual sufentanil is as or&#xD;
      more efficacious than a single dose of IV fentanyl in a post anesthesia care setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a level I randomized prospective outcomes study comparing two groups of patients.&#xD;
      Upon arrival in the ambulatory surgery center (ASC) post-anesthesia care unit (PACU) if the&#xD;
      patient has a pain score of 4 or greater they will then be randomized to one of two groups.&#xD;
      Group 1 will receive 50 mcg of IV fentanyl and group 2 will receive 30 mcg of sublingual&#xD;
      sufentanil. The primary outcome assessed will be time of readiness to discharge after arrival&#xD;
      in the post-anesthesia care unit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 11, 2019</start_date>
  <completion_date type="Actual">January 31, 2020</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery Room Time</measure>
    <time_frame>1 day</time_frame>
    <description>The time (reported in minutes) from when the patient arrives in the PACU, right after surgery, to the time that all discharge criteria are met.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rescue Milligram Morphine Equivalents (Opioid Use After Intervention Until Discharge)</measure>
    <time_frame>1 day</time_frame>
    <description>All doses of opioid medications administered following initial dosage (sufentanil or fentanyl depending on study arm) will be converted to milligram morphine equivalents and summed for reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 day</time_frame>
    <description>Number of serious adverse events (grades 3, 4, and 5) experienced by each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Nausea and Vomiting (PONV)</measure>
    <time_frame>1 day</time_frame>
    <description>Number of participants in each arm who are treated for nausea and/or vomiting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supplemental Oxygen</measure>
    <time_frame>1 day</time_frame>
    <description>Number of participants in each arm who require supplemental oxygen therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Benefit of Analgesic Score (OBAS)</measure>
    <time_frame>1 day</time_frame>
    <description>Overall Benefit of Analgesic Score (OBAS) is a 7-item multi-dimensional survey that assesses analgesia benefits. Items are scored on a scale from 0 (minimal) to 4 (maximal). Total score is a sum of the 7 item scores with question 7 scored as 4 minus the patient reported number. Total scores range from 0 to 28 with lower scores representing greater benefit from analgesic therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Pain</condition>
  <condition>Pain, Acute</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Sublingual Sufentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of sublingual sufentanil for acute pain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Fentanyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose of IV fentanyl for acute pain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual Sufentanil</intervention_name>
    <description>30 mcg of sublingual sufentanil</description>
    <arm_group_label>Sublingual Sufentanil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Fentanyl</intervention_name>
    <description>50 mcg of IV fentanyl</description>
    <arm_group_label>IV Fentanyl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  undergoing outpatient ambulatory surgery&#xD;
&#xD;
          -  recipient of general anesthesia&#xD;
&#xD;
          -  pain score of 4 or greater in the PACU&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  non-english speaking patients&#xD;
&#xD;
          -  cancer surgeries&#xD;
&#xD;
          -  patients who have allergy or intolerance to the study drugs or derivatives&#xD;
&#xD;
          -  patients on chronic opioids (defined as daily opioids for 3 months or longer)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron M Berg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 22, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <results_first_submitted>January 12, 2021</results_first_submitted>
  <results_first_submitted_qc>January 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 2, 2021</results_first_posted>
  <last_update_submitted>April 15, 2021</last_update_submitted>
  <last_update_submitted_qc>April 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT04177862/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were assigned to groups after undergoing their surgical procedures if they had a self-reported pain score of 4 and above on the 11-point numeric rating scale during phase 1 of PACU.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sublingual Sufentanil</title>
          <description>Single dose of sublingual sufentanil for acute pain.&#xD;
Sublingual Sufentanil: 30 mcg sublingual sufentanil tablet</description>
        </group>
        <group group_id="P2">
          <title>IV Fentanyl</title>
          <description>single dose of IV fentanyl for acute pain.&#xD;
IV Fentanyl: 50 mcg of IV fentanyl</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sublingual Sufentanil</title>
          <description>Single dose of sublingual sufentanil for acute pain.&#xD;
Sublingual Sufentanil: 30 mcg sublingual sufentanil tablet</description>
        </group>
        <group group_id="B2">
          <title>IV Fentanyl</title>
          <description>single dose of IV fentanyl for acute pain.&#xD;
IV Fentanyl: 50 mcg of IV fentanyl</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" lower_limit="32.5" upper_limit="58"/>
                    <measurement group_id="B2" value="37" lower_limit="22.75" upper_limit="53.75"/>
                    <measurement group_id="B3" value="42" lower_limit="25.5" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recovery Room Time</title>
        <description>The time (reported in minutes) from when the patient arrives in the PACU, right after surgery, to the time that all discharge criteria are met.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sublingual Sufentanil</title>
            <description>Single dose of sublingual sufentanil for acute pain.&#xD;
Sublingual Sufentanil: 30 mcg sublingual sufentanil tablet</description>
          </group>
          <group group_id="O2">
            <title>IV Fentanyl</title>
            <description>single dose of IV fentanyl for acute pain.&#xD;
IV Fentanyl: 50 mcg of IV fentanyl</description>
          </group>
        </group_list>
        <measure>
          <title>Recovery Room Time</title>
          <description>The time (reported in minutes) from when the patient arrives in the PACU, right after surgery, to the time that all discharge criteria are met.</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" lower_limit="56.0" upper_limit="89.0"/>
                    <measurement group_id="O2" value="65.0" lower_limit="56.0" upper_limit="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Milligram Morphine Equivalents (Opioid Use After Intervention Until Discharge)</title>
        <description>All doses of opioid medications administered following initial dosage (sufentanil or fentanyl depending on study arm) will be converted to milligram morphine equivalents and summed for reporting.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sublingual Sufentanil</title>
            <description>Single dose of sublingual sufentanil for acute pain.&#xD;
Sublingual Sufentanil: 30 mcg sublingual sufentanil tablet</description>
          </group>
          <group group_id="O2">
            <title>IV Fentanyl</title>
            <description>single dose of IV fentanyl for acute pain.&#xD;
IV Fentanyl: 50 mcg of IV fentanyl</description>
          </group>
        </group_list>
        <measure>
          <title>Rescue Milligram Morphine Equivalents (Opioid Use After Intervention Until Discharge)</title>
          <description>All doses of opioid medications administered following initial dosage (sufentanil or fentanyl depending on study arm) will be converted to milligram morphine equivalents and summed for reporting.</description>
          <units>milligram morphine equivalents</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="7.5" upper_limit="30.0"/>
                    <measurement group_id="O2" value="22.5" lower_limit="13.1" upper_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Number of serious adverse events (grades 3, 4, and 5) experienced by each group</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sublingual Sufentanil</title>
            <description>Single dose of sublingual sufentanil for acute pain.&#xD;
Sublingual Sufentanil: 30 mcg sublingual sufentanil tablet</description>
          </group>
          <group group_id="O2">
            <title>IV Fentanyl</title>
            <description>single dose of IV fentanyl for acute pain.&#xD;
IV Fentanyl: 50 mcg of IV fentanyl</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Number of serious adverse events (grades 3, 4, and 5) experienced by each group</description>
          <units>SAEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Nausea and Vomiting (PONV)</title>
        <description>Number of participants in each arm who are treated for nausea and/or vomiting.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sublingual Sufentanil</title>
            <description>Single dose of sublingual sufentanil for acute pain.&#xD;
Sublingual Sufentanil: 30 mcg of sublingual sufentanil</description>
          </group>
          <group group_id="O2">
            <title>IV Fentanyl</title>
            <description>single dose of IV fentanyl for acute pain.&#xD;
IV Fentanyl: 50 mcg of IV fentanyl</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Nausea and Vomiting (PONV)</title>
          <description>Number of participants in each arm who are treated for nausea and/or vomiting.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Supplemental Oxygen</title>
        <description>Number of participants in each arm who require supplemental oxygen therapy</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sublingual Sufentanil</title>
            <description>Single dose of sublingual sufentanil for acute pain.&#xD;
Sublingual Sufentanil: 30 mcg sublingual sufentanil tablet</description>
          </group>
          <group group_id="O2">
            <title>IV Fentanyl</title>
            <description>single dose of IV fentanyl for acute pain.&#xD;
IV Fentanyl: 50 mcg of IV fentanyl</description>
          </group>
        </group_list>
        <measure>
          <title>Supplemental Oxygen</title>
          <description>Number of participants in each arm who require supplemental oxygen therapy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Benefit of Analgesic Score (OBAS)</title>
        <description>Overall Benefit of Analgesic Score (OBAS) is a 7-item multi-dimensional survey that assesses analgesia benefits. Items are scored on a scale from 0 (minimal) to 4 (maximal). Total score is a sum of the 7 item scores with question 7 scored as 4 minus the patient reported number. Total scores range from 0 to 28 with lower scores representing greater benefit from analgesic therapy.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sublingual Sufentanil</title>
            <description>Single dose of sublingual sufentanil for acute pain.&#xD;
Sublingual Sufentanil: 30 mcg sublingual sufentanil tablet</description>
          </group>
          <group group_id="O2">
            <title>IV Fentanyl</title>
            <description>single dose of IV fentanyl for acute pain.&#xD;
IV Fentanyl: 50 mcg of IV fentanyl</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Benefit of Analgesic Score (OBAS)</title>
          <description>Overall Benefit of Analgesic Score (OBAS) is a 7-item multi-dimensional survey that assesses analgesia benefits. Items are scored on a scale from 0 (minimal) to 4 (maximal). Total score is a sum of the 7 item scores with question 7 scored as 4 minus the patient reported number. Total scores range from 0 to 28 with lower scores representing greater benefit from analgesic therapy.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sublingual Sufentanil</title>
          <description>Single dose of sublingual sufentanil for acute pain.&#xD;
Sublingual Sufentanil: 30 mcg sublingual sufentanil tablet</description>
        </group>
        <group group_id="E2">
          <title>IV Fentanyl</title>
          <description>single dose of IV fentanyl for acute pain.&#xD;
IV Fentanyl: 50 mcg of IV fentanyl</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Postoperative nausea</sub_title>
                <description>Postoperative nausea</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jonah Pearson</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>218-280-8348 ext 1</phone>
      <email>pears731@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

